期刊
NEW ENGLAND JOURNAL OF MEDICINE
卷 364, 期 17, 页码 1595-1606出版社
MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMoa1100391
关键词
-
资金
- NIH Office of Rare Disease Research [RR019498, RR019259]
- Food and Drug Administration [FD003362]
- Canadian Institutes of Health Research
- Pfizer (formerly Wyeth) Pharmaceuticals
- Japanese Ministry of Health, Labor, and Welfare [H-19-Rinshoshiken-008]
- Tuberous Sclerosis Alliance
- Cincinnati Children's Hospital Medical Center [1UL1RR026314-01]
- Vi and John Adler
- Adler Foundation
- Division of Intramural Research, National Heart, Lung, and Blood Institute
- Pfizer
BACKGROUND Lymphangioleiomyomatosis (LAM) is a progressive, cystic lung disease in women; it is associated with inappropriate activation of mammalian target of rapamycin (mTOR) signaling, which regulates cellular growth and lymphangiogenesis. Sirolimus (also called rapamycin) inhibits mTOR and has shown promise in phase 1-2 trials involving patients with LAM. METHODS We conducted a two-stage trial of sirolimus involving 89 patients with LAM who had moderate lung impairment - a 12-month randomized, double-blind comparison of sirolimus with placebo, followed by a 12-month observation period. The primary end point was the difference between the groups in the rate of change (slope) in forced expiratory volume in 1 second (FEV1). RESULTS During the treatment period, the FEV1 slope was -12 +/- 2 ml per month in the placebo group (43 patients) and 1 +/- 2 ml per month in the sirolimus group (46 patients) (P<0.001). The absolute between-group difference in the mean change in FEV1 during the treatment period was 153 ml, or approximately 11% of the mean FEV1 at enrollment. As compared with the placebo group, the sirolimus group had improvement from baseline to 12 months in measures of forced vital capacity, functional residual capacity, serum vascular endothelial growth factor D (VEGF-D), and quality of life and functional performance. There was no significant between-group difference in this interval in the change in 6-minute walk distance or diffusing capacity of the lung for carbon monoxide. After discontinuation of sirolimus, the decline in lung function resumed in the sirolimus group and paralleled that in the placebo group. Adverse events were more common with sirolimus, but the frequency of serious adverse events did not differ significantly between the groups. CONCLUSIONS In patients with LAM, sirolimus stabilized lung function, reduced serum VEGF-D levels, and was associated with a reduction in symptoms and improvement in quality of life. Therapy with sirolimus may be useful in selected patients with LAM.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据